Nazopass (Oxymetazoline Hydrochloride)

Oxymetazoline hydrochloride is a selective alpha‑1 and alpha‑2 adrenergic receptor agonist. When applied to the nasal mucosa, it triggers vasoconstriction of the small blood vessels, decreasing mucosal edema and allowing the nasal passages to clear.

The appropriate dose of Nazopass is determined by a qualified prescriber based on the patient’s age, condition, and response. The product is intended for short‑term use, typically not exceeding three to five consecutive days.

Safety data for oxymetazoline hydrochloride in pregnancy and lactation are limited. It should be used only if the potential benefit justifies the potential risk, and only after consultation with a healthcare professional.

To place an order, submit an enquiry on the Nazopass product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Nazopass contains oxymetazoline, a potent alpha‑adrenergic agonist that provides rapid relief of congestion. Compared with older agents such as phenylephrine, oxymetazoline generally offers a longer duration of action and a lower incidence of rebound congestion when used as directed.

Nazopass should be stored at room temperature, below 25 °C, in its original packaging. Keep the container tightly closed, protect it from moisture and direct sunlight, and avoid storing it in bathrooms or other humid environments.

Nazopass is applied intranasally. The recommended technique is to tilt the head slightly forward, insert the tip into one nostril, and spray the prescribed number of sprays. Repeat in the other nostril if directed, and avoid blowing the nose immediately after administration.

Serious risks, though uncommon, include significant elevation of blood pressure, rapid heart rate, arrhythmias, and rebound nasal congestion (rhinitis medicamentosa) after prolonged use. Patients experiencing these symptoms should discontinue use and seek medical attention promptly.

Nazopass should be avoided by individuals with known hypersensitivity to oxymetazoline or any excipients, patients with severe hypertension, coronary artery disease, or uncontrolled cardiovascular disorders, and children under six years of age unless specifically prescribed by a physician.